ConductScience.org, home

Paper · 33022971

The Immune Microenvironment in Pancreatic Cancer.

Huber M and 9 others. Int J Mol Sci, 2020. Cited by 208 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The Immune Microenvironment in Pancreatic Cancer. Papers, record 33022971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33022971

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Immune Microenvironment in Pancreatic Cancer.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
208
iCite
Relative citation ratio, by iCite
8.6
iCite
Revised in PubMed
2024-04-03
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huber MMagdalenahttps://orcid.org/0000-0002-2963-0693
2Brehm CUCorinna Uhttps://orcid.org/0000-0002-4312-1377
3Gress TMThomas Mhttps://orcid.org/0000-0002-9333-5461
4Buchholz MMalte
5Alashkar Alhamwe BBilal
6von Strandmann EPElke Pogge
7Slater EPEmily P
8Bartsch JWJörg Whttps://orcid.org/0000-0002-2773-3357
9Bauer CChristian
10Lauth MMatthias

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Carcinoma, Pancreatic DuctalMajor topic
Tumor MicroenvironmentMajor topic
Humans
Immunotherapy

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
KFO325Deutsche ForschungsgemeinschaftPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References239

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,494,847Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC).Oncotarget2016https://conductscience.org/library/papers/27494847PubMed
221,654,544The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms.Pancreas2011https://conductscience.org/library/papers/21654544PubMed
331,695,760Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8.Theranostics2019https://conductscience.org/library/papers/31695760PubMed
429,443,960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
532,657,929Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.Ann Surg2020https://conductscience.org/library/papers/32657929PubMed
623,007,469Protumor and antitumor functions of neutrophil granulocytes.Semin Immunopathol2013https://conductscience.org/library/papers/23007469PubMed
731,350,295The Tumor Microenvironment Innately Modulates Cancer Progression.Cancer Res2019https://conductscience.org/library/papers/31350295PubMed
822,996,369Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.J Immunother2012https://conductscience.org/library/papers/22996369PubMed
926,321,679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
1023,056,397Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.PLoS One2012https://conductscience.org/library/papers/23056397PubMed

Cited by164

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 208 citations.

PMIDTitleJournalYearIn PapersSource
42,877,184Development of tRNA-based biomarkers for breast cancer: insight from machine learning.Arch Med Sci2026https://conductscience.org/library/papers/42877184PubMed
42,792,545Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma.Biology (Basel)2026https://conductscience.org/library/papers/42792545PubMed
42,737,789Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progression and Resistance Through Supplement Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42737789PubMed
42,720,867Targeting lncRNA-regulated macrophage polarization: a novel therapeutic strategy for pancreatic ductal adenocarcinoma.J Physiol Biochem2026https://conductscience.org/library/papers/42720867PubMed
42,648,752Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.J Immunother Cancer2026https://conductscience.org/library/papers/42648752PubMed
42,624,885Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma.NPJ Precis Oncol2026https://conductscience.org/library/papers/42624885PubMed
42,553,398Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade.Front Immunol2026https://conductscience.org/library/papers/42553398PubMed
42,332,796Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer.BMC Pharmacol Toxicol2026https://conductscience.org/library/papers/42332796PubMed
42,265,391Characterizing pancreatic cancer-associated fibroblast heterogeneity in vascular microphysiological systems.Angiogenesis2026https://conductscience.org/library/papers/42265391PubMed
42,233,178High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls: Implications for Cancer Care.Cancer Med2026https://conductscience.org/library/papers/42233178PubMed

1 to 10 of 164

See all 164 cited by

Genes119

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33022971

GET https://conductscience.org/api/papers/v1/33022971/references?page=2